The MarketWatch News Department was not involved in the creation of this content.

December 02, 2020 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / December 2, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

First American Financial Corp. (NYSE:FAF)Class Period: February 17, 2017 – October 22, 2020Lead Plaintiff Deadline: December 24, 2020

The FAF lawsuit alleges that throughout the class period, First American Financial Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in FAF: http://www.kleinstocklaw.com/pslra-1/first-american-financial-corp-loss-submission-form?id=11320&from=1

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Class Period: September 28, 2019 – October 7, 2020Lead Plaintiff Deadline: January 4, 2021

During the class period, Intercept Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid (“OCA”)), Intercept’s lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration (“FDA”) investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating nonalcoholic steatohepatitis (“NASH”) were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ICPT: http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11320&from=1

Berry Corporation (NASDAQ:BRY)Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company’s initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusiveLead Plaintiff Deadline: January 21, 2021

The complaint alleges that throughout the class period Berry Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry’s operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company’s productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company’s revenues; and (iv) as a result, the Offering Documents and the Company’s public statements were materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in BRY: http://www.kleinstocklaw.com/pslra-1/berry-corporation-loss-submission-form?id=11320&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY [email protected]: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/619237/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FAF-ICPT-and-BRY

COMTEX_375425083/2457/2020-12-02T16:25:25

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2020 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Source Article